Winrevair (sotatercept-csrk), compared to placebo, reduced the risk of all-cause death, lung transplantation, and hospitalization.

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25 ...

A team of pharmaceutical researchers at Novartis Biomedical Research, working with an international team of associates, has ...

The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by ...

Research reveals how specific sleep stages protect brain vulnerable to Alzheimer's, offering hope through simple lifestyle ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders, today announced the enrollment of ...

Toxicity information from phase 3 oncology clinical trials often is incomplete and interpreted in ways that minimize its ...

CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier ...

IHL-42X is designed to treat OSA by targeting its underlying pathophysiology. An oral fixed-dose combination of dronabinol and acetazolamide, IHL-42X is currently advancing through the RePOSA Phase ...

In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...

In March 2025, Juventas Cell Therapy Ltd. conducted a phase Ib/II trial to evaluate the safety and efficacy of CNCT19 ...

Carrillo, MD, evaluates the current state of the global availability of clinical trials for patients with renal cell ...